Loading...
Despite the success of current antiretroviral treatments, researchers continue to try to simplify therapy, with the goal of making treatment easier for patients and less expensive overall. Two simplification strategies were described at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention: dropping ritonavir from a PI-based treatment regimen (AIRES) and dropping the non-PI companion drugs from darunavir-based regimens (MONET and MONOI-ANRS 136).
The industry-sponsored AIRES trial involved 419 patients who achieved viral loads <50 copies/mL while receiving abacavir/3TC + ritonavir-boosted atazanavir and were then randomized to continue the same treatment or to discontinue ritonavir and increase the atazanavir dose from 300 mg …